Barbara Savoldo Selected Research

Neoplasms (Cancer)

1/2024	IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity.
12/2023	Building safety into CAR-T therapy.
12/2023	ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
12/2022	Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β.
2/2022	The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma.
1/2022	Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
1/2022	Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.
1/2022	Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells.
11/2021	CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells.
10/2021	Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Savoldo Research Topics

Disease

84	Neoplasms (Cancer) 01/2024 - 01/2002
13	Hematologic Neoplasms (Hematological Malignancy) 12/2023 - 09/2008
12	Neuroblastoma 01/2024 - 11/2008
10	Hodgkin Disease (Hodgkin's Disease) 03/2024 - 10/2007
10	Lymphoma (Lymphomas) 03/2024 - 05/2011
8	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2015 - 08/2009
5	Melanoma (Melanoma, Malignant) 01/2022 - 09/2008
5	Infections 06/2015 - 08/2009
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2024 - 12/2006
4	Leukemia 01/2024 - 11/2011
4	Glioblastoma (Glioblastoma Multiforme) 12/2022 - 01/2018
4	Multiple Myeloma 03/2019 - 07/2002
4	Virus Diseases (Viral Diseases) 04/2014 - 09/2005
3	Cytokine Release Syndrome 01/2023 - 06/2015
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2021 - 12/2006
3	Testicular Neoplasms (Testicular Cancer) 09/2014 - 09/2008
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 05/2006 - 01/2002
2	Brain Neoplasms (Brain Tumor) 12/2022 - 01/2022
2	Lung Neoplasms (Lung Cancer) 01/2022 - 01/2022
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 11/2013
2	Breast Neoplasms (Breast Cancer) 01/2020 - 06/2007
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2019 - 01/2019
2	B-Cell Lymphoma (Lymphoma, B Cell) 05/2011 - 12/2006
2	Inflammation (Inflammations) 01/2010 - 07/2009
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022
1	Retinoblastoma (Glioblastoma, Retinal) 10/2020
1	Retinal Neoplasms 10/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Ovarian Neoplasms (Ovarian Cancer) 11/2019
1	Adenocarcinoma 11/2019
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2018
1	Embryonal Carcinoma 10/2018
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 09/2017
1	Lymphopenia (Lymphocytopenia) 01/2016

Drug/Important Bio-Agent (IBA)

54	Chimeric Antigen ReceptorsIBA 01/2024 - 06/2007
33	AntigensIBA 01/2022 - 07/2002
8	CytokinesIBA 11/2021 - 05/2006
8	Interleukin-15 (Interleukin 15)IBA 11/2020 - 10/2007
7	Interleukin-2 (IL2)IBA 06/2014 - 06/2007
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2009
4	EpitopesIBA 10/2019 - 12/2011
3	Monoclonal AntibodiesIBA 12/2023 - 06/2007
3	Ki-1 AntigenIBA 01/2022 - 06/2009
3	fludarabineIBA 11/2020 - 06/2015
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2018 - 06/2015
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018 - 01/2015
3	CD19-specific chimeric antigen receptorIBA 01/2016 - 10/2013
3	AutoantigensIBA 01/2015 - 07/2002
3	Interleukin-7 (Interleukin 7)IBA 06/2014 - 05/2009
3	Antiviral Agents (Antivirals)IBA 10/2013 - 04/2010
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2023 - 09/2014
2	Messenger RNA (mRNA)IBA 01/2022 - 05/2015
2	Immunoglobulins (Immunoglobulin)IBA 11/2021 - 12/2006
2	InterleukinsIBA 10/2020 - 01/2013
2	GD2 gangliosideIBA 10/2020 - 09/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020 - 01/2018
2	AntibodiesIBA 01/2019 - 09/2009
2	CD19 AntigensIBA 01/2017 - 05/2011
2	VaccinesIBA 01/2016 - 01/2013
2	AP 1903 reagentIBA 06/2015 - 11/2011
2	SurvivinIBA 01/2015 - 12/2011
2	Viral AntigensIBA 10/2013 - 01/2013
2	HLA Antigens (Human Leukocyte Antigens)IBA 12/2011 - 08/2009
2	ChemokinesIBA 01/2010 - 06/2009
2	Chemokine ReceptorsIBA 01/2010 - 06/2009
1	Interleukin-12 (IL 12)IBA 01/2024
1	Caspase 9IBA 12/2023
1	Anaplastic Lymphoma KinaseIBA 12/2023
1	tazemetostatIBA 01/2022
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2022
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	CCR2 ReceptorsIBA 01/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 11/2021
1	FibrinIBA 10/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	HydrogelsIBA 10/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2020
1	Interleukin-18 (Interleukin 18)IBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Panitumumab (Vectibix)FDA Link 01/2020
1	Cancer VaccinesIBA 10/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	I-E-antigenIBA 10/2018
1	chondroitin sulfate proteoglycan 4IBA 01/2018
1	Immune Checkpoint InhibitorsIBA 01/2017

Therapy/Procedure

30	Therapeutics 03/2024 - 06/2005
28	Immunotherapy 01/2024 - 01/2002
6	Stem Cell Transplantation 03/2024 - 01/2002
4	Transplantation 03/2024 - 08/2009
3	Drug Therapy (Chemotherapy) 12/2019 - 11/2012
3	Hematopoietic Stem Cell Transplantation 01/2014 - 08/2009
3	Liver Transplantation 11/2006 - 09/2005
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2018 - 01/2018
1	Salvage Therapy 03/2024
1	Intravenous Administration 10/2021
1	Injections 10/2020